tirzepatide loss of exclusivity Off-patent semaglutide in 2026: the next revolution in anti-obesity medications tirzepatide loss of exclusivity Tirzepatide

Doses of semaglutide ranging from 0.1-1.6 mg resulted in a 2.1%, 7.0%, 13.0%, 37.5%, 51.2%, and 63.6% respective dose-dependent increases in the proportion of patients that achieved a 5%, or greater, reduction in weight loss

Flux redistribution of central carbon metabolism for efficient production of ltryptophan in Escherichia coli

True semaglutide allergies are uncommon and present with systemic symptoms like breathing difficulty or widespread hives

Funding Medical writing and editorial support were provided by Ashfield MedComms, an Inizio company, and funded by Ardelyx, Inc

From molecular design to clinical translation: dual-targeted CAR-T strategies in cancer immunotherapy